Abivax presented 22 abstracts at the European Crohn's and Colitis Organisation conference, showcasing preclinical evidence that obefazimod exhibits anti-fibrotic activity alongside clinical efficacy in inflammatory bowel disease patients. The biotech company's research revealed upregulation of miR-124 and significant reductions in inflammatory cytokines IL-17A and IL-6, suggesting a multi-mechanism approach to treating IBD. Safety data demonstrated a tolerability profile comparable to placebo across the company's clinical programs.
The presentations included new analyses from ongoing clinical trials examining obefazimod's rapid symptomatic improvements in ulcerative colitis patients. The data support the drug candidate's potential to address both inflammation and tissue remodeling pathways implicated in IBD progression. These findings represent an expansion of obefazimod's therapeutic profile beyond symptomatic relief to potential disease modification.
Abivax expects to report results from its Phase 3 maintenance trial in the second quarter of 2026, followed by Phase 2b ENHANCE-CD trial readout in the fourth quarter of 2026. These upcoming data releases will be critical in advancing obefazimod's development trajectory toward potential regulatory approval.